Supplement Material 1

Interview Guide and Example Questions

Theme 1 Background and attitudes towards substitution

- Would you briefly describe how you are dealing with the generic substitution that is currently taking place in the community pharmacies?
- How well do you know the biological originator medicines and the biosimilars and how have you been dealing with them?
- What do you think about the possibility of biologics' substitution in the community pharmacies?
- Is the current generic substitution model also suitable for the implementation of the biologics' substitution?

Theme 2 Medication safety of biologics' substitution

- What should be taken into account in order to ensure the medication safety if the substitution of biologics is introduced in the community pharmacies?
- How often could you expect the substitution would take place to an individual patient?
- Should the number of switches or timing of switches be limited in some manner?
- Considering substitution, there any differences between different indications or drugs?

Theme 3 Prerequisites for substitution (These questions are related to the community pharmacy activity. In the theme 3, issues were different for each perspective)

- Under what conditions do you consider that biologics substitution in community pharmacy could work?
- What kind of skills or training would be needed for community pharmacists?
- What should be considered for the implementation of drug counseling?
- What would be the effects of biologics' substitution at a pharmacy level on treatment adherence, management of pharmacotherapy and monitoring of treatment?
- How to secure the batch number and traceability of the biological medicinal product?
- What should be considered from the drug storage point of view?

Theme 4 Implementation and monitoring of potential biologics substitution

- If substitution takes place in time, how would you like to see a change in practice?
- How should your organization / workplace / interest group and other stakeholders be involved in preparation for deployment?
- How the implementation of the substitution should be monitored?
- Is there something that has not been dealt with now, but which should be taken into account with substitution of biologics?